EDITORIALS

When the Risk of Febrile Neutropenia Is 20%, Prophylactic Colony-Stimulating Factor Use Is Clinically Effective, but Is It Cost-Effective?

Jared R. Adams, Cara Angelotta, and Charles L. Bennett

JCO Jul 1 2006: 2975–2977. First published on May 8 2006; 10.1200/JCO.2006.05.6812. [Full Text] [PDF]

Postoperative Radiotherapy in Non—Small-Cell Lung Cancer Warrants Further Exploration in the Era of Adjuvant Chemotherapy and Conformal Radiotherapy

James A. Bonner and Sharon A. Spencer

JCO Jul 1 2006: 2978–2980. First published on Jun 12 2006; 10.1200/JCO.2006.05.8560. [Full Text] [PDF]

Lately, It Occurs to Me What a Long, Strange Trip It's Been for the Farnesyltransferase Inhibitors

Eric K. Rowinsky

JCO Jul 1 2006: 2981–2984. First published on Jun 12 2006; 10.1200/JCO.2006.05.9808. [Full Text] [PDF]

Can Granulocyte-Colony Stimulating Factor Worsen Anemia?

Chau Dang and Clifford Hudis

JCO Jul 1 2006: 2985–2986. First published on Jun 12 2006; 10.1200/JCO.2006.06.1416. [Full Text] [PDF]

COMMENTS AND CONTROVERSIES

Rethinking Risk-Benefit Assessment for Phase I Cancer Trials

Steven Joffe and Franklin G. Miller

JCO Jul 1 2006: 2987–2990. [Full Text] [PDF]

ORIGINAL REPORTS
Statistical/Economic Analysis
	Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung Cancer
	Johanna N.H. Timmer-Bonte, Eddy M.M. Adang, Hans J.M. Smit, Bonne Biesma, Frank A. Wilschut, Gerben P. Bootsma, Theo M. de Boo, and Vivianne C.G. Tjan-Heijnen
	JCO Jul 1 2006: 2991–2997. First published on May 8 2006; 10.1200/JCO.2005.04.3281. [Abstract] [Full Text] [PDF]

Lung Cancer
	Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database
	Brian E. Lally, Daniel Zelterman, Joseph M. Colasanto, Bruce G. Haffty, Frank C. Detterbeck, and Lynn D. Wilson
	JCO Jul 1 2006: 2998–3006. First published on Jun 12 2006; 10.1200/JCO.2005.04.6110. [Abstract] [Full Text] [PDF] [Russian PDF]
	Progression-Free Survival Rate As Primary End Point for Phase II Cancer Clinical Trials: Application to Mesothelioma—The EORTC Lung Cancer Group
	Julie Francart, Catherine Legrand, Richard Sylvester, Martine Van Glabbeke, Jan P. van Meerbeeck, and Annie Robert
	JCO Jul 1 2006: 3007–3012. [Abstract] [Full Text] [PDF]

Breast Cancer
	Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide
	Joseph A. Sparano, Stacy Moulder, Aslamuzzaman Kazi, Linda Vahdat, Tianhong Li, Christine Pellegrino, Pam Munster, Mokenge Malafa, David Lee, Shira Hoschander, Una Hopkins, Dawn Hershman, John J. Wright, and Said M. Sebti
	JCO Jul 1 2006: 3013–3018. First published on Jun 12 2006; 10.1200/JCO.2005.04.9114. [Abstract] [Full Text] [PDF]
	Estrogen-Independent Proliferation Is Present in Estrogen-Receptor HER2-Positive Primary Breast Cancer After Neoadjuvant Letrozole
	Matthew J. Ellis, Yu Tao, Oliver Young, Sharon White, Alan D. Proia, Julliette Murray, Lorna Renshaw, Dana Faratian, Jeremy Thomas, Mitch Dowsett, Andreas Krause, Dean B. Evans, William R. Miller, and J. Michael Dixon
	JCO Jul 1 2006: 3019–3025. First published on Jun 5 2006; 10.1200/JCO.2005.04.3034. [Abstract] [Full Text] [PDF]
	Powerful Prognostic Stratification By [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy
	Florent Cachin, H. Miles Prince, Annette Hogg, Robert E. Ware, and Rodney J. Hicks
	JCO Jul 1 2006: 3026–3031. First published on May 22 2006; 10.1200/JCO.2005.04.6326. [Abstract] [Full Text] [PDF]
	HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
	Edith A. Perez, Vera J. Suman, Nancy E. Davidson, Silvana Martino, Peter A. Kaufman, Wilma L. Lingle, Patrick J. Flynn, James N. Ingle, Daniel Visscher, and Robert B. Jenkins
	JCO Jul 1 2006: 3032–3038. [Abstract] [Full Text] [PDF]
	Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor–Positive Breast Cancer
	Brian Z. Ring, Robert S. Seitz, Rod Beck, William J. Shasteen, Shannon M. Tarr, Maggie C.U. Cheang, Brian J. Yoder, G. Thomas Budd, Torsten O. Nielsen, David G. Hicks, Noel C. Estopinal, and Douglas T. Ross
	JCO Jul 1 2006: 3039–3047. [Abstract] [Full Text] [PDF] [Supplementary Data]

Treatment-Related Complications
	Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?
	Paola Papaldo, Gianluigi Ferretti, Serena Di Cosimo, Diana Giannarelli, Paolo Marolla, Massimo Lopez, Enrico Cortesi, Mauro Antimi, Edmondo Terzoli, Paolo Carlini, Patrizia Vici, Claudio Botti, Luigi Di Lauro, Giuseppe Naso, Cecilia Nisticò, Marcella Mottolese, Franco Di Filippo, Enzo Maria Ruggeri, Anna Ceribelli, and Francesco Cognetti
	JCO Jul 1 2006: 3048–3055. First published on Jun 12 2006; 10.1200/JCO.2005.02.9488. [Abstract] [Full Text] [PDF]
	Phase II Trial of Alfimeprase, a Novel-Acting Fibrin Degradation Agent, for Occluded Central Venous Access Devices
	Stephan Moll, Peter Kenyon, Luigi Bertoli, James De Maio, Howard Homesley, and Steven R. Deitcher
	JCO Jul 1 2006: 3056–3060. [Abstract] [Full Text] [PDF]

Gastrointestinal Cancer
	The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer
	Giuseppe Toffoli, Erika Cecchin, Giuseppe Corona, Antonio Russo, Angela Buonadonna, Mario D'Andrea, Lara Maria Pasetto, Sergio Pessa, Domenico Errante, Vincenzo De Pangher, Mauro Giusto, Michele Medici, Fernando Gaion, Paolo Sandri, Enzo Galligioni, Salvatore Bonura, Massimo Boccalon, Paola Biason, and Sergio Frustaci
	JCO Jul 1 2006: 3061–3068. [Abstract] [Full Text] [PDF]
	Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer
	Philip A. Philip, Michelle R. Mahoney, Cristine Allmer, James Thomas, Henry C. Pitot, George Kim, Ross C. Donehower, Tom Fitch, Joel Picus, and Charles Erlichman
	JCO Jul 1 2006: 3069–3074. [Abstract] [Full Text] [PDF]

Genitourinary Cancer
	Phase I Trial of Intravesical Docetaxel in the Management of Superficial Bladder Cancer Refractory to Standard Intravesical Therapy
	James M. McKiernan, Puneet Masson, Alana M. Murphy, Manlio Goetzl, Carl A. Olsson, Daniel P. Petrylak, Manisha Desai, and Mitchell C. Benson
	JCO Jul 1 2006: 3075–3080. [Abstract] [Full Text] [PDF]
	Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment
	Anna C. Ferrari, Nelson N. Stone, Ralf Kurek, Elizabeth Mulligan, Roy McGregor, Richard Stock, Pamela Unger, Ulf Tunn, Amir Kaisary, Michael Droller, Simon Hall, Heiner Renneberg, Kenneth J. Livak, Robert E. Gallagher, and John Mandeli
	JCO Jul 1 2006: 3081–3088. [Abstract] [Full Text] [PDF]
	Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer
	Eric J. Small, Paul F. Schellhammer, Celestia S. Higano, Charles H. Redfern, John J. Nemunaitis, Frank H. Valone, Suleman S. Verjee, Lori A. Jones, and Robert M. Hershberg
	JCO Jul 1 2006: 3089–3094. [Abstract] [Full Text] [PDF]
	Formulas Calculating Creatinine Clearance Are Inadequate for Determining Eligibility for Cisplatin-Based Chemotherapy in Bladder Cancer
	Ganesh V. Raj, Alexia Iasonos, Harry Herr, and Sherri Machele Donat
	JCO Jul 1 2006: 3095–3100. [Abstract] [Full Text] [PDF]
	Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence
	Scott E. Eggener, Ofer Yossepowitch, Joseph A. Pettus, Mark E. Snyder, Robert J. Motzer, and Paul Russo
	JCO Jul 1 2006: 3101–3106. [Abstract] [Full Text] [PDF]

Hematologic Malignancies
	Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin’s Lymphoma Resulting in Durable Clinical Responses
	Charles H. Redfern, Troy H. Guthrie, Alberto Bessudo, John J. Densmore, Peter R. Holman, Nalini Janakiraman, John P. Leonard, Richard L. Levy, Richard G. Just, Mitchell R. Smith, Fred P. Rosenfelt, Peter H. Wiernik, William D. Carter, Daniel P. Gold, Teresa J. Melink, John C. Gutheil, and John F. Bender
	JCO Jul 1 2006: 3107–3112. First published on Jun 5 2006; 10.1200/JCO.2005.04.4289. [Abstract] [Full Text] [PDF]
	Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib
	Paul G. Richardson, Hannah Briemberg, Sundar Jagannath, Patrick Y. Wen, Bart Barlogie, James Berenson, Seema Singhal, David S. Siegel, David Irwin, Michael Schuster, Gordan Srkalovic, Raymond Alexanian, S. Vincent Rajkumar, Steven Limentani, Melissa Alsina, Robert Z. Orlowski, Kevin Najarian, Dixie Esseltine, Kenneth C. Anderson, and Anthony A. Amato
	JCO Jul 1 2006: 3113–3120. First published on Jun 5 2006; 10.1200/JCO.2005.04.7779. [Abstract] [Full Text] [PDF]
	Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
	Thomas M. Habermann, Edie A. Weller, Vicki A. Morrison, Randy D. Gascoyne, Peter A. Cassileth, Jeffrey B. Cohn, Shaker R. Dakhil, Bruce Woda, Richard I. Fisher, Bruce A. Peterson, and Sandra J. Horning
	JCO Jul 1 2006: 3121–3127. First published on Jun 5 2006; 10.1200/JCO.2005.05.1003. [Abstract] [Full Text] [PDF] [Russian PDF]
	Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials
	Evert M. Noordijk, Patrice Carde, Noëlle Dupouy, Anton Hagenbeek, Augustinus D.G. Krol, Johanna C. Kluin-Nelemans, Umberto Tirelli, Mathieu Monconduit, José Thomas, Houchingue Eghbali, Berthe M.P. Aleman, Jacques Bosq, Marjeta Vovk, Tom A.M. Verschueren, Anne-Marie Pény, Théodore Girinsky, John M.M. Raemaekers, and Michel Henry-Amar
	JCO Jul 1 2006: 3128–3135. First published on Jun 5 2006; 10.1200/JCO.2005.05.2746. [Abstract] [Full Text] [PDF]
	Assessment of Disease Dissemination in Gastric Compared With Extragastric Mucosa-Associated Lymphoid Tissue Lymphoma Using Extensive Staging: A Single-Center Experience
	Markus Raderer, Stefan Wöhrer, Berthold Streubel, Marlene Troch, Karl Turetschek, Ulrich Jäger, Cathrin Skrabs, Alexander Gaiger, Johannes Drach, Andreas Puespoek, Michael Formanek, Martha Hoffmann, Wolfgang Hauff, and Andreas Chott
	JCO Jul 1 2006: 3136–3141. First published on Jun 12 2006; 10.1200/JCO.2006.06.0723. [Abstract] [Full Text] [PDF]

Pediatric Oncology
	Isolated CNS Relapse of Acute Lymphoblastic Leukemia Treated With Intensive Systemic Chemotherapy and Delayed CNS Radiation: A Pediatric Oncology Group Study
	Julio C. Barredo, Meenakshi Devidas, Stephen J. Lauer, Amy Billett, MaryAnne Marymont, Jeanette Pullen, Bruce Camitta, Naomi Winick, William Carroll, and A. Kim Ritchey
	JCO Jul 1 2006: 3142–3149. [Abstract] [Full Text] [PDF]
	Bone Marrow Transplantation Versus Prolonged Intensive Chemotherapy for Children With Acute Lymphoblastic Leukemia and an Initial Bone Marrow Relapse Within 12 Months of the Completion of Primary Therapy: Children's Oncology Group Study CCG-1941
	Paul S. Gaynon, Richard E. Harris, Arnold J. Altman, Bruce C. Bostrom, John C. Breneman, Ria Hawks, David Steele, Theodore Zipf, Daniel O. Stram, Doodjuen Villaluna, and Michael E. Trigg
	JCO Jul 1 2006: 3150–3156. First published on May 22 2006; 10.1200/JCO.2005.04.5856. [Abstract] [Full Text] [PDF]

Melanoma
	Phase II Multicenter Study of Neoadjuvant Biochemotherapy for Patients With Stage III Malignant Melanoma
	Karl D. Lewis, William A. Robinson, Martin McCarter, Nathan Pearlman, Steven J. O'Day, Clay Anderson, Thomas T. Amatruda, Anna Baron, Chan Zeng, Maude Becker, Susan Dollarhide, Karen Matijevich, and Rene Gonzalez
	JCO Jul 1 2006: 3157–3163. [Abstract] [Full Text] [PDF]
	Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses
	Stergios J. Moschos, Howard D. Edington, Stephanie R. Land, Uma N. Rao, Drazen Jukic, Janice Shipe-Spotloe, and John M. Kirkwood
	JCO Jul 1 2006: 3164–3171. [Abstract] [Full Text] [PDF]
	Anatomic Site, Sun Exposure, and Risk of Cutaneous Melanoma
	David C. Whiteman, Mark Stickley, Peter Watt, Maria Celia Hughes, Marcia B. Davis, and Adèle C. Green
	JCO Jul 1 2006: 3172–3177. [Abstract] [Full Text] [PDF]

REVIEW ARTICLE
	Health-Related Quality of Life Measurement in Randomized Clinical Trials in Surgical Oncology
	Jane M. Blazeby, Kerry Avery, Mirjam Sprangers, Hynek Pikhart, Peter Fayers, and Jenny Donovan
	JCO Jul 1 2006: 3178–3186. [Abstract] [Full Text] [PDF]

ASCO SPECIAL ARTICLES
	2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
	Thomas J. Smith, James Khatcheressian, Gary H. Lyman, Howard Ozer, James O. Armitage, Lodovico Balducci, Charles L. Bennett, Scott B. Cantor, Jeffrey Crawford, Scott J. Cross, George Demetri, Christopher E. Desch, Philip A. Pizzo, Charles A. Schiffer, Lee Schwartzberg, Mark R. Somerfield, George Somlo, James C. Wade, James L. Wade, Rodger J. Winn, Antoinette J. Wozniak, and Antonio C. Wolff
	JCO Jul 1 2006: 3187–3205. First published on May 8 2006; 10.1200/JCO.2006.06.4451. [Abstract] [Full Text] [PDF]
	Reimbursement for Cancer Treatment: Coverage of Off-Label Drug Indications
	Revised February 27, 2006, by the American Society of Clinical Oncology
	JCO Jul 1 2006: 3206–3208. First published on May 22 2006; 10.1200/JCO.2006.06.8940. [Abstract] [Full Text] [PDF]

ART OF ONCOLOGY

Learning to Listen: A Fellow's Experience

Lanie K. Francis

JCO Jul 1 2006: 3209–3210. [Full Text] [PDF]

CORRESPONDENCE

What About the Family When a Terminally Ill Cancer Patient Makes a Request for Euthanasia?

Christof Schäfer, Barbara Dietl, Thomas H. Loew, and Oliver Kölbl

JCO Jul 1 2006: 3211–3212. [Full Text] [PDF]

In Reply

Marije L. van der Lee, Johanna G. van der Bom, Nikkie B. Swarte, A. Peter M. Heintz, Alexander de Graeff, and Jan van den Bout

JCO Jul 1 2006: 3212–3213. [Full Text] [PDF]

Promising New Treatment Schedule for Gefitinib Responders After Severe Hepatotoxicity With Daily Administration

Nobuhiko Seki, Kazutsugu Uematsu, Reishi Shibakuki, and Kenji Eguchi

JCO Jul 1 2006: 3213–3214. [Full Text] [PDF]

In Reply

Cheryl Ho, Gwyn Bebb, and Nevin Murray

JCO Jul 1 2006: 3214–3215. [Full Text] [PDF]

Important Bias in the Astragalus Meta-Analysis

Fabio Firenzuoli, Luigi Gori, Luisa Di Simone, and Maria Morsuillo

JCO Jul 1 2006: 3215–3216. [Full Text] [PDF]

In Reply

Michael F. McCulloch, Caylie See, Xiao-juan Shu, Michael D. Broffman, Alan Kramer, Wei-yu Fan, Jin Gao, Whitney Lieb, Kane Shieh, and John M. Colford, Jr

JCO Jul 1 2006: 3216–3217. [Full Text] [PDF]

Breaking Bad News: More Than Just Guidelines

Walter F. Baile, Robert Buckman, Lidia Schapira, and Patricia A. Parker

JCO Jul 1 2006: 3217. [Full Text] [PDF]

In Reply

Susan Eggly, Louis A. Penner, Terrance L. Albrecht, Rebecca J.W. Cline, Tanina Foster, Michael Naughton, Amy Peterson, and John C. Ruckdeschel

JCO Jul 1 2006: 3217-a–3218. [Full Text] [PDF]

Cytogenetic Abnormalities Can Change During the Course of the Disease Process in Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Diane Jelinek, Renee Tschumper, Susan Schwager, Grzegorz Nowakowski, Gordon W. DeWald, and Neil E. Kay

JCO Jul 1 2006: 3218–3219. [Full Text] [PDF]

In Reply

Alexander Kröber, Hartmut Döhner, and Stephan Stilgenbauer

JCO Jul 1 2006: 3219–3220. [Full Text] [PDF]

ERRATA

ERRATUM

JCO Jul 1 2006: 3221. [Full Text] [PDF]

ERRATUM

JCO Jul 1 2006: 3221-a. [Full Text] [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.